SCHEMBL16294249

SCHEMBL16294249

COc1ccccc1-c1csc2ncncc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 16/20 0.54
CYP1A2 P05177 15/20 0.54
HSD17B10 Q99714 10/20 0.54
TDP1 Q9NUW8 5/20 0.54
ALDH1A1 P00352 5/20 0.54
CYP2C19 P33261 14/20 0.50
CYP2D6 P10635 13/20 0.50
ALOX15 P16050 7/20 0.50
LMNA P02545 5/20 0.50
TSHR P16473 8/20 0.48
CLK4 Q9HAZ1 3/20 0.48
CYP2C9 P11712 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPK1 P28482 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.46
PIP4K2C Q8TBX8 1/20 0.46
ATM Q13315 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14964882 0.74 FGFR1 (0.53) CYP1A2ALDH1A1CYP2C19LMNACLK4
SCHEMBL14965146 0.74 KMT2A (0.42) CYP3A4CYP1A2HSD17B10TDP1ALDH1A1
SCHEMBL2368752 0.73 PKM (0.53) CYP3A4CYP1A2HSD17B10TDP1ALDH1A1
SCHEMBL2369304 0.72 CYP2A6 (0.51) MAPK1CYP19A1
SCHEMBL2368808 0.69 LMNA (0.55) ALDH1A1LMNAMEN1KMT2AMAPK1
SCHEMBL29429633 0.69 CA1 (0.71) CYP3A4CYP1A2HSD17B10TDP1ALDH1A1
SCHEMBL6754272 0.69 CYP1A2 (0.54) CYP3A4CYP1A2HSD17B10TDP1ALDH1A1
SCHEMBL29788337 0.69 CA1 (0.71) CYP3A4CYP1A2HSD17B10TDP1ALDH1A1
SCHEMBL174453 0.69 CYP1A2 (0.54) CYP3A4CYP1A2HSD17B10TDP1ALDH1A1
SCHEMBL301996 0.69 CA1 (0.71) CYP3A4CYP1A2HSD17B10TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160152634-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2016-06-02 US disclosed
US-9290511-B2 Thieno-pyrimidines, useful as potassium channel inhibitors XENTION LIMITED (GB) 2016-03-22 US disclosed
US-20140371203-A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors XENTION LIMITED (GB) 2014-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371203-A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors KCNA3, KCNJ1, KCNJ11 CYP3A4 682/4885CYP1A2 1211/4885HSD17B10 4161/4885
US-20160152634-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS KCNA3, KCNJ1, KCNJ11 CYP3A4 556/4885CYP1A2 1075/4885HSD17B10 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.